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(JADAS-27). Uni- and multivariable analyses were per-
formed.
Results: A total of 275 patients were included. The
prevalence of underweight, normal weight, overweight
and obesity was 6.9%, 67.3%, 15.3% and 10.5%, re-
spectively. Underweight patients had significantly high-
er number of active joints (p<0.001), patient’s/parent’s
global assessment of disease activity (PGA) (p=0.020),
physician’s global assessment of disease activity (PhGA)
(p<0.001), erythrocyte sedimentation rate (ESR)
(p=0.032) and overall higher JADAS-27 (p<0.001),
compared to patients with normal weight, overweight
and obesity. 
In the multivariable regression, normal weight 
(B=-9.43, p<0.01), overweight (B=-9.30, p=0.01) and
obesity (B=-9.12, p=0.01) were significantly associated
with lower disease activity compared to underweight,
when adjusted for age, gender, country, ethnicity, JIA
category and therapies used. The diagnosis of 
RF- (B=3.65, p=0.006) or RF+ polyarticular JIA
(B=5.29, p=0.024), the absence of DMARD therapy
(B=5.54, p<0.001) and the use of oral GC (B=4.98,
p=0.002) were also associated with higher JADAS-27.
Conclusion: We found an independent association be-
tween underweight and higher disease activity in pa-
tients with JIA. Further studies are needed to under-
stand the underlying mechanisms of this association.
Keywords: Juvenile idiopathic arthritis; Body mass in-
dex;
IntroductIon
Juvenile Idiopathic Arthritis (JIA) is the most common
chronic rheumatic disease in childhood. It comprises a
group of heterogeneous conditions with distinct phe-
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AbstrAct 
Objective: To investigate the relationship between
body mass index (BMI) and disease activity in patients
with Juvenile Idiopathic Arthritis (JIA).
Methods: Patients with JIA, aged ≤18 years, registered
at the Rheumatic Diseases Portuguese Register
(Reuma.pt) in Portugal and Brazil were included. Age-
and sex-specific BMI percentiles were calculated based
on WHO growth standard charts and categorized into
underweight (P<3), normal weight (3≤P≤85), over-
weight (85<P≤97) and obesity (P>97). Disease activity
was assessed by Juvenile Arthritis Disease Activity Score
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notypes and variable course and prognosis1. Over the
last years, new treatment options have offered major
improvements in long-term outcomes2. Yet, some chil-
dren still fail to achieve disease remission and experi-
ence persistent or recurrent arthritis into adulthood3,4.
A systematic review revealed that less than 50% of pa-
tients achieve sustained remission in the first ten years
following diagnosis, even in contemporary cohorts5.
Young age at onset, female gender, diagnostic delay,
symmetric disease, systemic or polyarticular subtypes,
presence of rheumatoid factor (RF) or anti-cyclic cit-
rullinated peptide antibodies (ACPA), and high levels
of erythrocyte sedimentation rate (ESR) or C-reactive
protein (CRP) have been suggested as predictors of
persistent active disease, although not unanimously
across different studies6-8. 
The influence of body mass index (BMI) on JIA
disea se activity is poorly studied. In adults with
Rheumatoid Arthritis (RA), obesity has been associa -
ted with high disease activity, a decrease in the odds of
achieving remission9,10 and an impaired quality of life11.
Likewise, weight loss (≥5 kg) was associated with a
significant improvement in RA disease activity12. A po-
tential explanation is through the role of adipose tis-
sue on the activation of pro-inflammatory path-
ways13,14. Several adipokines (leptin, resistin, visfatin,
among others) secrete various cytokines such as TNF,
IL-1 , IL-6, which bear pro-inflammatory properties,
resulting in more active disease in obese patients. On
the other hand, increased body weight can be partly
caused by lack of physical activity, due to joint pain,
stiffness, fatigue or other short or long-term disabili-
ties.
Paradoxically, some studies have revealed an inverse
relationship between BMI and the risk of radiograph-
ic progression in RA15-17. Furthermore, a cross-sectional
study showed that, in addition to obesity, underweight
was also associated with increased disease activity in
RA18.
Given the observations in RA we hypothesize that
there is an association between BMI and JIA disease
activity. Thus, in this study, we aim to test if this asso-
ciation exists.
MAterIAls And Methods
study desIgn And populAtIon
This is a cross-sectional analysis based on the
Rheumatic Diseases Portuguese Register (Reuma.pt)19.
Reuma.pt is a prospective longitudinal real-world data
registry developed by the Portuguese Society of
Rheumatology to record data from patients with vari-
ous rheumatic diseases, including JIA. Partnerships
have been done with centers in other countries, name-
ly Brazil, which have the same version of the database
for their own use.
Patients with JIA, according to the 2001 revised In-
ternational League of Associations for Rheumatology
(ILAR) criteria20, aged ≤ 18 years, who were registered
in Reuma.pt in Portugal and Brazil up to May 2019 and
who had available data on BMI and disease activity
were included.
For registry of data in Reuma.pt, parent’s informed
consent and patient’s assent were obtained, as appro-
priate. This study was approved by the scientific com-
mittee of Reuma.pt and by the Ethics Committee of
Centro Hospitalar de Lisboa Ocidental (registry num-
ber 20170700050). Reuma.pt was approved by the Na-
tional Committee for Data Protection. The study was
conducted according to the Declaration of Helsinki.
dAtA collectIon
The following data were collected at the time of the first
visit registered in Reuma.pt: age, gender, ethnicity,
country, BMI, JIA category according to ILAR classifi-
cation criteria, disease duration, number of swollen and
tender joints, patient’s/parent’s pain visual analogue
scale (VAS 0-10cm), patient’s/parent’s global assessment
of disease activity (PGA, VAS 0-10 cm), physician’s
global assessment of disease activity (PhGA, VAS 0-10
cm), ESR, CRP and current therapy with glucocorti-
coids (GC), conventional and biological disease-mo -
difying antirheumatic drugs (DMARDs).
Disease activity was assessed by Juvenile Arthritis
Disease Activity Score 27-joint reduced count (JADAS-
-27)21, a composite validated score. The overall JADAS-
-27 score ranges from 0 (no activity) to 57 (highest di -
sease activity). For all JIA categories, the state of inactive
disease was defined as JADAS-27≤1, a validated cutoff
developed by Consolaro et al22.
Age- and gender-specific BMI percentiles (P) were
calculated based on World Health Organization
(WHO) growth standard charts (23). According to their
BMI percentiles, patients were allocated into four dif-
ferent categories: underweight (P<3), normal weight
(3≤P≤85), overweight (85<P≤97) and obesity (P>97).
stAtIstIcAl AnAlysIs
Categorical variables are shown as frequencies and per-
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centages. Continuous variables are presented as mean
and standard deviation (SD). Normal distribution was
assessed using Kolmogorov–Smirnov test.
Fisher’s exact test, chi-square test or one-way analy -
sis of variance (as appropriate) were used to compare
demographic and clinical characteristics between diffe -
rent BMI categories. Differences between countries
(Portugal and Brazil) were examined using t-test, Fi -
sher’s exact test or chi-square test.
Linear regression was used to investigate the associ-
ation of JADAS-27 with BMI categories. To correct for
possible confounding effects, two multivariable linear
regression models were developed. Model 1 was ad-
justed for age, gender, ethnicity, country, disease dura-
tion and JIA category. Model 2 was adjusted for those
covariates plus use of DMARDs and glucocorticoids.
Statistical significance was defined as a p-value of
less than 0.05. Statistical Package for Social Science
(SPSS) version 23 was used for data analysis.
results
A total of 275 patients from 20 different centers were
included in this study. Nearly 88% were from Portugal
and 12% from Brazil. Most patients (62.2%) were fe-
male. Overall, the mean age at the first registered visit
was 10.2 ± 4.6 years, and the mean disease duration
was 1.7 ± 2.9 years. Persistent oligoarticular (31.9%),
rheumatoid factor-negative (RF-) polyarticular (25.9%)
and enthesitis-related arthritis (14.8%) were the most
prevalent JIA categories. Mean JADAS-27 was 7.1 ± 6.9
and 22.2% of patients had inactive disease. Only 10.2%
of patients were on glucocorticoids; 65.4% were on
conventional DMARDs (cDMARDs) and 14.9% on bio -
logical DMARDs (bDMARDs).
The prevalence of underweight, normal weight,
overweight and obesity was 6.9%, 67.3%, 15.3% and
10.5%, respectively. Table I shows the distribution of
the demographic and clinical characteristics of patients
grouped by BMI categories. There were no significant
differences in terms of age, gender, country, ethnicity,
disease duration, use of GC, cDMARDs or bDMARDs
between groups. Persistent oligoarticular was the most
prevalent JIA category for all groups, except for un-
derweight patients, who had predominantly enthesi-
tis-related arthritis. Still, this difference concerning JIA
categories did not reach statistical significance
(p=0.063).
Patients from Brazil had significantly lower disease
duration (0.8 ± 2.3 vs 1.9 ± 2.9 years, p=0.009) and
higher JADAS-27 scores (9.9 ± 10.6 vs 6.7 ± 7.1,
p=0.002), compared to those from Portugal. Nonethe-
less, there were no significant differences between
countries in terms of age, gender, JIA category, thera-
pies used and, importantly, prevalence of BMI cate-
gories.
Overall, there was a statistically significant differen -
ce in JADAS-27 mean scores between BMI categories.
A post-hoc test using Tukey’s method revealed that un-
derweight patients had significantly higher JADAS-27
scores than normal weight (p<0.001), overweight
(p<0.001) and obese patients (p=0.014). Meanwhile,
there were no significant differences in JADAS-27 mean
between normal weight and overweight or obesity
groups, though the latter had slightly higher absolute
values (Table I).
The same findings were observed for each of the in-
dividual components of JADAS-27 (Figure 1). Under-
weight patients had significantly higher number of ac-
tive joints, higher PGA, PhGA and ESR, comparing to
the other groups. Regarding CRP, there was no statisti-
cally significant difference between the four groups, al-
though underweight patients had the highest absolute
CRP values, followed by obese patients.
To further evaluate the association of BMI and JIA
disease activity, linear models were performed (Table
II). In the univariable linear regression, underweight
was significantly associated with higher JADAS-27,
compared to normal weight, overweight and obesity.
Younger age, shorter disease duration, black race, liv-
ing in Brazil, RF- polyarthritis, RF+ polyarthritis, the
absence of DMARD therapy and the use of GC were
also associated with higher JADAS-27.
In the model 1 of multivariable analysis, the same
variables, except the country, remained significantly as-
sociated with higher disease activity. When GC and
DMARD therapies were added to the model (model 2),
the association of normal weight, overweight and obe-
sity with lower disease activity persisted significant,
compared to underweight patients, as well as those un-
der DMARD therapy. The presence of RF- or RF+ pol-
yarthritis and the use of oral GC were associated with
higher JADAS-27.
dIscussIon
We found an independent association between under-
weight and higher disease activity in patients with JIA.
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In fact, underweight patients have higher ESR, patient
or parent global assessment, physician global assess-
ment, number of active joints, and overall higher
JADAS-27 scores, comparing to patients with normal
weight, overweight and obesity.
The association between the use of systemic GC and
higher disease activity reflects the need of a potent and
rapidly effective therapeutic option, in order to achieve
a more rapid disease control. On the other hand, the
use of DMARD therapy was associated with lower
disea se activity, as expected.
Our study included patients from two different
countries. In spite of that, there were no significant dif-
ferences in patients’ characteristics between countries,
with the exception of a lower disease duration and
higher JADAS-27 scores in Brazilian patients. This
could be the result of an entry of patients into the
Reuma.pt database earlier in the course of the disease,
when control of disease activity is still less achieved.
The lack of use of biological therapies in Brazilian pa-
tients is also in line with an earlier disease state. In any
case, there were no differences regarding BMI categories
between Portuguese and Brazilian patients.
Only a few studies have addressed the impact of BMI
on JIA disease activity. In 2012, Pelajo et al. performed
a cross-sectional analysis of 154 subjects, of whom 18%
were obese and 12% overweight, but failed to find any
association between BMI and JADAS-27 scores24. On
tAble I. deMogrAphIc And clInIcAl chArActerIstIcs of JIA pAtIents by bMI  
All Underweight Normal weight Overweight Obesity p-value
Age, years (mean ± SD) 10.2 ± 4.6 12.8 ± 4.8 10.0 ± 4.6 9.7 ± 4.9 10.5 ± 4.7 0.09
Females, n (%) 171 (62) 10 (53) 116 (63) 27 (64) 18 (62) 0.84
Country (Portugal), n (%) 243 (88) 15 (79) 163 (88) 40 (95) 25 (86) 0.29
Ethnicity, n (%) (n=221)
European Caucasian 194 (88) 9 (82) 129 (88) 33 (85) 23 (92)
Non-European Caucasian 8 (4) 0 6 (4) 2 (5) 0
Black 8 (4) 2 (18) 3 (2) 2 (5) 1 (4) 0.69
Biracial 6 (3) 0 4 (3) 1 (3) 1 (4)
Romani 2 (1) 0 2 (1) 0 0
Asiatic 3 (1) 0 2 (1) 1 (23) 0
JIA category,  n (%) (n=263)
Persistent oligoarthritis 84 (32) 1 (6) 61 (34) 13 (33) 9 (33)
Extended oligoarthritis 22 (8) 1 (6) 13 (7) 7 (18) 1 (4)
RF-negative polyarthritis 68 (26) 6 (33) 46 (26) 9 (23) 7 (26)
RF-positive polyarthritis 19 (7) 3 (17) 13 (7) 0 3 (11)
Systemic-onset 15 (6) 0 8 (5) 5 (13) 2 (7)
0.06
Enthesitis-related arthritis 39 (15) 7 (39) 25 (14) 4 (10) 3 (11)
Psoriatic arthritis 14 (5) 0 11 (6) 1 (3) 2 (7)
Undifferentiated arthritis 2 (1) 0 2 (1) 0 0
Disease duration, years  1.7 ± 2.9 2.0 ± 3.1 1.6 ± 2.8 1.4 ± 2.6 2.8 ± 2.5 0.69
(mean ± SD) (n=255)
JADAS-27 (mean ± SD) 7.1 ± 6.9 18.7 ± 10.7 5.9 ± 7.0 5.4 ± 7.0 8.8 ± 10.3 <0.01
Inactive disease1, n (%) 61 (22) 0 44 (24) 11 (26) 6 (21) 0.11
GC use, n (%) 28 (10) 3 (16) 21 (11) 1 (2) 3 (10) 0.29
GC dosage, mg/kg/day 0.3 ±0.2 0.30 ±0.1 0.24 ±0.2 0.24 ± 0 0.31± 0.2 0.60
(mean ± SD)2
cDMARD use, n, % (n=188) 123 (65) 9 (69) 86 (67) 14 (56) 14 (67) 0.76
bDMARD use, n, % (n=188) 28 (15) 4 (31) 19 (15) 3 (12) 2 (10) 0.36
1. Defined as JADAS-27≤1. 
2. Prednisolone dose or equivalent.
JIA: Juvenile Idiopathic Arthritis; RF: rheumatoid factor; JADAS-27: Juvenile Arthritis Disease Activity Score 27-joint reduced count; GC:
glucocorticoids; cDMARD: conventional disease-modifying antirheumatic drugs; bDMARD: biological disease-modifying antirheumatic drugs.
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the other hand, in another study involving 72 patients
with enthesitis-related arthritis, it was shown that 
being overweight or obese was associated with failure
to achieve clinically inactive disease at one year after the
initiation of therapy. The inactive disease status was de-
fined by the Wallace criteria plus the absence of active
enthesitis or inflammatory back pain25. In both studies,
underweight patients were grouped under normal
weight, due to the small number (n≤5) of individuals
in this former category.
More recently, an Italian single-center retrospective
study evaluated 110 patients with JIA, of whom 80
were healthy weighted and 30 were overweight or
obese26. Once again, there was no significant difference
between BMI and ESR, CRP or total number of active
joints, although involvement of the joints of lower
limbs was significantly higher in overweight or obese
patients, comparing to normal weight patients. Lower
remission rates were also observed in overweight/obese
patients, although without statistical significance. In
this study, underweight patients were not included.
Similar to these previous studies, our data also
showed that obese patients might have a trend toward
unfavorable disease activity outcomes, comparing to
normal weighted patients, as illustrated in Figure 1, al-
though the difference was not statistically significant.
Nonetheless, considering our results and those from
other studies, the association between obesity and dis-
ease activity in JIA seems to be less evident than in RA.
However, individuals with the same BMI do not nec-
essarily have the same body composition and, before
the onset of puberty, weight gain is mostly based on
fat-free mass rather than fat-mass27. Hence, we should
be careful when interpreting different data from the pe-
diatric and adult populations. The use of distinct tools
to assess disease activity in JIA and RA also challenges
the comparison of both entities.
Nearly one-quarter of patients in our sample were
overweight or obese. This rate is similar to the one re-
cently reported in the Childhood Obesity Surveillance
Initiative (COSI Portugal 2019), a program aimed at
monitoring the obesity epidemic in Portuguese chil-
dren aged between 6 and 8 years, in which 29.6% were
overweight or obese28. On the other hand, there was a
higher rate of underweight patients (6.9%) in our co-
hort, compared to the COSI sample (1.3%).
To the best of our knowledge, this is the first study
identifying an independent association between low
weight and high disease activity in JIA. The underlying
mechanism of this association is still unclear, although
we hypothesize that active disease can impair child’s
weight gain. Reduced BMI can be the result of high
chronic systemic inflammation that can lead to cachex-
ia, in particular, to poor appetite, loss of lean mass and
increased metabolic rate29, 30. Longitudinal studies are
needed to corroborate this hypothesis. Additionally, a
previous study has shown that temporomandibular
joint (TMJ) involvement in children with JIA is associa -
fIgure 1. Disease activity parameters by BMI category. 
BMI: Body mass index; PGA: Patient’s/parent’s global assessment of disease activity; PhGA: physician’s global assessment of disease
activity; VAS: Visual Analogue Scale.  
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tAble II. relAtIonshIp between JAdAs-27 (dependent vArIAble) And deMogrAphIc And clInIcAl 
chArActerIstIcs of JIA pAtIents.
Multivariate analysis
Univariate analysis Model 1 (R2 = 0.235) Model 2 (R2 = 0.303)
B [95% CI] B [95% CI] B [95% CI]
Age, years -0.28 [-0.50 – (-0.06)] -0.36 [-0.70-(-0.26)]
Disease duration, years -0.36 [-0.58-(-0.14)]
Gender (female) 0.08 [-2.06 – 2.22]
Country (Portugal) -5.40 [-8.58- (-2.23)]
Ethnicity
European Caucasian*
Non-European Caucasian -3.65 [-9.79- 2.49]






Extended oligoarthritis -1.24 [-5.08-2.60]
RF-positive polyarthritis 6.20 [3.63-8.78] 7.08 [3.22 – 10.93] 5.29 [0.71 – 9.87]
RF-negative polyarthritis 8.76 [4.68-12.85] 4.90 [2.60 – 7.20] 3.65 [1.04 – 6.27]
Systemic-onset 3.02 [-1.49-7.53]
Enthesitis-related arthritis 2.21 [-0.88-5.29]
Psoriatic arthritis 2.94 [-1.72-7.59]
Undifferentiated arthritis 9.00 [-2.61-20.61]
BMI
Underweight*
Normal weight -9.87 [-13.84 – (-5.89)] -9.43 [-13.34-(-5.52)] -9.43 [-13.75-(-5.11)]
Overweight -10.60 [-15.16 – (-6.04)] -9.31 [-13.82-(-4.80)] -9.30 [-14.48-(-4.11)]
Obesity -7.51 [-12.38 – (-2.64)] -7.31 [-12.12-(-2.50)] -9.12 [-14.45-(-3.80)]
Oral GC use 4.15 [0.76 – 7.55] 4.98 [1.82 - 8.15]
cDMARD use -3.40 [-5.89-(-0.78)] –
bDMARD use -2.71 [-6.15 - 0.74] –
Any DMARD use -4.91 [-7.49-(-2.34)] -5.54 [-7.94-(-3.15)]
*Reference group
Model 1: adjusted for age, gender, ethnicity, country, disease duration and JIA category.
Model 2: adjusted for those covariates plus use of GC and DMARDs.
ted with higher disease activity31. In our cohort, only
5% of patients had TMJ involvement (data not shown).
Due to the very low number of patients affected, this
variable was not included in the statistical analysis.
However, we may hypothesize that patients with TMJ
involvement may encounter some mechanical difficul-
ties in eating, possibly affecting their nutrition and BMI.
Limitations of our study include the cross-sectional
design even though the analysis was nested in a
prospective longitudinal study, the low number of un-
derweight patients, and the lack of data regarding so-
cioeconomic status, education level of parents or care-
takers, physical activity and nutrition, all of which
could influence BMI. Moreover, the sample size was
not sufficiently large to perform subgroup analysis and
draw accurate conclusions for each JIA category, which
would be relevant since JIA is not a single disease, but
a group of heterogeneous conditions. In enthesitis-re-
lated arthritis, JADAS-27 disregards key features of the
disease, such as axial involvement and enthesitis.
Hence, a different instrument for assessment of disease
activity may be warranted for this JIA category, al-
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though these patients were also included in the valida-
tion study of JADAS21.
Regarding the definition of inactive disease by Con-
solaro et al, the authors are aware that in the original
validation analysis of the cutoff, JIA patients were ag-
gregated in only two groups (oligoarthritis and pol-
yarthritis) based on the number of affected joints22.
Consequently, cutoff values specific for systemic arthri-
tis, enthesitis-related arthritis, or psoriatic arthritis
could not be developed. In spite of that, since patients
with these ILAR categories were also included and as-
signed to one of the two groups in the cross-validation
analysis, we considered acceptable to apply this defi-
nition to all JIA patients in our study.
Lastly, BMI has an inherent inability to distinguish
between lean and fat mass32. Thus, the evaluation of
body composition by another method, such as bio-
electrical impedance analysis would have been more
accurate to assess body mass. In conclusion, in JIA, low
weight seems to be independently related to high dis-
ease activity. Further studies are needed to confirm
these findings and understand the underlying mecha-
nisms of this association. Importantly, the routine as-
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